Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230016/S005

MAGE-A4 IHC 1F9 pharmDx

Agilent Technologies, Inc. · Decision date Sep 11, 2026

MEDTECHLEDGER EXPLANATIONP230016/S005

What did the FDA decide?

The FDA recorded a decision dated 2026-09-11 on supplement P230016/S005 for MAGE-A4 IHC 1F9 pharmDx, an immunohistochemistry antibody assay in the Pathology specialty under product code SBL, submitted by Agilent Technologies, Inc. The supplement is a 30-Day Notice with the recorded reason Process Change - Manufacturer/Sterilizer/Packager/Supplier.

The recorded statement covers approval of manufacturing process and equipment changes for filling and capping. This is a supplement action tied to the existing P230016 file, not a new approval of the assay as a whole. The source lists no supporting documents, so the specific filling and capping equipment, sites and validation data behind the change are not identified here, and the decision code OK30 is not expanded in the available record.

Whether the changed filling and capping steps affect assay performance or labeling cannot be determined from this record; that question would require the underlying FDA review documents, which are not included.

FDA approval order statement

approval of manufacturing process and equipment changes for filling and capping
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Pathology
Decision date
Sep 11, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P230016/S005
Regulatory pathway
PMA supplement
Product code
SBL
Decision code
OK30
Decision date
Sep 11, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Immunohistochemistry Assay, Antibody, Melanoma-associated antigen A4.

Product code
SBL
FDA device class
3

For the original device and its historical approval scope, see PMA P230016. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230016 · Original PMA

    MAGE-A4 IHC 1F9 pharmDx

  2. P230016/S005 received

    Application receipt date recorded by FDA.

  3. P230016/S005 · FDA decision

    30-Day Notice

  4. P230016/S003 · Related supplement

    MAGE-A4 IHC 1F9 pharmDx

  5. P230016/S004 · Related supplement

    MAGE-A4 IHC 1F9 pharmDx

Timeline entries are records held by MedtechLedger for P230016. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230016

Product / regulatory recordCompanyPathwayDecision dateSource
Agilent Technologies, Inc.PMA approvalAug 1, 2024FDA
Agilent Technologies, Inc.PMA supplementSep 15, 2026FDA
Agilent Technologies, Inc.PMA supplementSep 21, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Agilent Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6392 Via Real, Carpinteria, CA, 93013

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records